HMGB1-mediated early loss of transplanted islets is prevented by anti-IL-6R antibody in mice

Pancreas

Volumn 44, Issue 1, 2015, Pages 166-171

  Itoh, Takeshi ^a   Nitta, Tomoyuki ^a   Nishinakamura, Hitomi ^a   Kojima, Daibo ^a   Mera, Toshiyuki ^a   Ono, Junko ^b   Kodama, Shohta ^a   Yasunami, Yohichi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Murakamikarindo Hospital   (Japan)

Author keywords

Anti IL 6R antibody; Graft loss; HMGB1; Islet transplantation

Indexed keywords

CD4 ANTIBODY; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; VOBARILIZUMAB; GLUCOSE BLOOD LEVEL; HMGB1 PROTEIN, MOUSE; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; INTERLEUKIN 6 RECEPTOR ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GRAFT FAILURE; GRAFT REJECTION; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; IMMUNOLOGY; LIVER; METABOLISM; PANCREAS ISLET; PATHOLOGY; TIME FACTOR; FLOW CYTOMETRY; GLUCOSE TOLERANCE; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HMGB1 PROTEIN; INTERFERON-GAMMA; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LIVER; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEUTROPHILS; RECEPTORS, INTERLEUKIN-6; TIME FACTORS;

EID: 84904519233     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000188     Document Type: Article

References (26)

1. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
2. McCall M, Shapiro AMJ. Update on islet transplantation. Cold Spring Harb Perspect Med. 2012;2:a007823.
3. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576-1583.
4. Yasunami Y, Kojo S, Kitamura H, et al. Vα14 NKT cell-triggered IFN-γ production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med. 2005;202:913-918.
5. MatsuokaN, Itoh T,WataraiH, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. 2010;120:735-743.
6. Itoh T, Iwahashi S, Kanak MA, et al. Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes. Cell Transplant. 2014;23:153-165.
7. Satoh M, Yasunami Y, Matsuoka N, et al. Successful islet transplantation to two recipients from a single donor by targeting proinflammatory cytokines in mice. Transplantation. 2007;83:1085-1092.
8. Taga T, Kishimoto T. GP130 and interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819.
9. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-1254.
10. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-626.
11. Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34:788-802.
12. Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-234.
13. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74: 1360-1367.
14. Nishimoto N, SasaiM, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000; 95:56-61.
15. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-2632.
16. Sutton R, McShane PM, Gray DWR, et al. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation. 1986;42:689-691.
17. Okeda T, Ono J, Takaki R, et al. Simple method for collection of pancreatic islets by the use of Ficoll-Conray gradient. Endocrinol Jpn. 1979;26: 495-499.
18. Kemp CB, Knight MJ, Scharp DW, et al. Transplantation of isolated pancreatic islets into the portal vein of rats. Nature. 1973;244:447.
19. Ohtsuka K, Yasunami Y, Ikehara Y, et al. Expansion of intermediate T cell receptor cells expressing IL-2Rα-β+, CD8α+β+, and lymphocyte function-associated antigen-1+ in the liver in association with intrahepatic islet xenograft rejection from rat to mouse: prevention of rejection with anti-IL-2Rβ monoclonal antibody treatment. Transplantation. 1997;64: 633-639.
20. Watarai H, Nakagawa R, Omori-Miyake M, et al. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc. 2008;3:70-78.
21. Nitta T, Itoh T, Matsuoka N, et al. Prevention of early loss of transplanted islets in the liver of mice by adenosine. Transplantation. 2009;88:49-56.
22. Kojima D, Mera T, Nishinakamura H, et al. Prevention of high-mobility group box 1-mediated early loss of transplantedmouse islets in the liver by antithrombin III. Transplantation. 2012;93:983-988.
23. Kojima D, Nishinakamura H, Ogata T, et al. Inhibitory effect of thrombomodulin on HMGB1-stimulated IFN-γ production of hepatic NKT and Gr-1+ cells, facilitating to prevent early loss of transplanted islets in the liver of mice. Transplantation. 2012;94:348.
24. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest. 2012;122: 3647-3651.
25. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039-2045.
26. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes. 2007;56:2008-2015.